Penny L. Moore

17.0k total citations · 2 hit papers
144 papers, 5.7k citations indexed

About

Penny L. Moore is a scholar working on Virology, Infectious Diseases and Immunology. According to data from OpenAlex, Penny L. Moore has authored 144 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Virology, 67 papers in Infectious Diseases and 59 papers in Immunology. Recurrent topics in Penny L. Moore's work include HIV Research and Treatment (100 papers), Immune Cell Function and Interaction (46 papers) and HIV/AIDS drug development and treatment (31 papers). Penny L. Moore is often cited by papers focused on HIV Research and Treatment (100 papers), Immune Cell Function and Interaction (46 papers) and HIV/AIDS drug development and treatment (31 papers). Penny L. Moore collaborates with scholars based in South Africa, United States and United Kingdom. Penny L. Moore's co-authors include Lynn Morris, Elin S. Gray, Salim S. Abdool Karim, Carolyn Williamson, Constantinos Kurt Wibmer, Koleka Mlisana, Tandile Hermanus, Bronwen E. Lambson, Michael T. Osterholm and Jinal N. Bhiman and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Penny L. Moore

132 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

2021 657 citations Constantinos Kurt Wibmer, Tandile Hermanus et al. profile →
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines

2022 133 citations Penny L. Moore et al. mBio profile →

Peers

Penny L. Moore

VIROL

IMMUN

RNMI

Jérôme H. Kim United States

Mark J. Newman United States

Shan Lu United States

Robert T. Bailer United States

Jean‐Louis Excler United States

Donald N. Forthal United States

Satish K. Pillai United States

A. R. Neurath United States

Eric Sandström Sweden

Anu Kantele Finland

Jérôme H. Kim United States

Penny L. Moore

2.0k ×0.6

VIROL

2.4k ×0.9

1.5k ×0.7

IMMUN

917 ×0.6

245 ×0.2

RNMI

Citations per year, relative to Penny L. Moore Penny L. Moore (= 1×) peers Jérôme H. Kim

Countries citing papers authored by Penny L. Moore

Since Specialization

Citations

This map shows the geographic impact of Penny L. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Penny L. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Penny L. Moore more than expected).

Fields of papers citing papers by Penny L. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Penny L. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Penny L. Moore. The network helps show where Penny L. Moore may publish in the future.

Co-authorship network of co-authors of Penny L. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Penny L. Moore. A scholar is included among the top collaborators of Penny L. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Penny L. Moore. Penny L. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pillay, Komala, Razia Hassan-Moosa, Wendy A. Burgers, et al.. (2025). Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review. AIDS Research and Therapy. 22(1). 44–44. 4 indexed citations

Daniels, Brodie, Zakir Gaffoor, Elizabeth Spooner, et al.. (2024). SARS-CoV-2 Infections in a Triad of Primary School Learners (Grades 1-7), Their Parents, and Teachers in KwaZulu-Natal, South Africa: Protocol for a Cross-Sectional and Nested Case-Cohort Study. JMIR Research Protocols. 13. e52713–e52713.

Nunes, Marta C., et al.. (2024). Hemagglutinin Stalk-Specific Fc-Mediated Functions Are Associated With Protection Against Influenza Illness After Seasonal Influenza Vaccination. The Journal of Infectious Diseases. 230(6). 1329–1336. 5 indexed citations

Lemmer, Yolandy, Rosamund Chapman, Célia Abolnik, et al.. (2024). Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters. Vaccine. 42(4). 738–744. 2 indexed citations

Moore, Penny L., Sharon Chen, Ellen Almirol, et al.. (2023). 301 Buprenorphine Induction in Emergency Department Patients Following Reversal of Non-Fatal Opioid Overdose With Naloxone. Annals of Emergency Medicine. 82(4). S132–S132. 1 indexed citations

Raju, Nagarajan, Prudence Kgagudi, Nelia P. Manamela, et al.. (2023). Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines. Journal of Virology. 98(1). e0147823–e0147823. 2 indexed citations

Moore, Penny L. & Glenda Gray. (2023). COVID-19 as a catalyst for vaccine manufacturing: A South African experience. Cell Host & Microbe. 31(6). 839–842.

Babady, N. Esther, et al.. (2022). Building a Resilient Scientific Network for COVID-19 and Beyond. mBio. 13(5). e0222322–e0222322. 1 indexed citations

Koff, Wayne C., Tere Williams, Ralph S. Baric, et al.. (2021). Development and deployment of COVID-19 vaccines for those most vulnerable. Science Translational Medicine. 13(579). 51 indexed citations

10.

Muenchhoff, Maximilian, Amy W. Chung, Julia Roider, et al.. (2020). Distinct Immunoglobulin Fc Glycosylation Patterns Are Associated with Disease Nonprogression and Broadly Neutralizing Antibody Responses in Children with HIV Infection. mSphere. 5(6). 17 indexed citations

11.

Richardson, Simone I., Bronwen E. Lambson, Andrew R. Crowley, et al.. (2019). IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. PLoS Pathogens. 15(12). e1008064–e1008064. 53 indexed citations

12.

Reh, Lucia, Carsten Magnus, Claus Kadelka, et al.. (2018). Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. PLoS Pathogens. 14(1). e1006825–e1006825. 10 indexed citations

13.

Johnson, E. L., Nicole A. Doria‐Rose, Jason Gorman, et al.. (2018). Sequencing HIV-neutralizing antibody exons and introns reveals detailed aspects of lineage maturation. Nature Communications. 9(1). 4136–4136. 6 indexed citations

14.

Richardson, Simone I., Amy W. Chung, Harini Natarajan, et al.. (2018). HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. PLoS Pathogens. 14(4). e1006987–e1006987. 56 indexed citations

15.

Wibmer, Constantinos Kurt, Daniel J. Sheward, Jinal N. Bhiman, et al.. (2014). Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. AIDS Research and Human Retroviruses. 30(S1). A20–A21. 1 indexed citations

16.

Gray, Elin S., Penny L. Moore, Ralph Pantophlet, & Lynn Morris. (2007). N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization. Journal of Virology. 81(19). 10769–10776. 40 indexed citations

17.

Moore, Penny L., Elin S. Gray, Isaac Choge, et al.. (2007). The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. Journal of Virology. 82(4). 1860–1869. 125 indexed citations

18.

Choge, Isaac, Tonie Cilliers, Polly Walker, et al.. (2006). Genotypic and Phenotypic Characterization of Viral Isolates from HIV-1 Subtype C-Infected Children with Slow and Rapid Disease Progression. AIDS Research and Human Retroviruses. 22(5). 458–465. 45 indexed citations

19.

Cilliers, Tonie, Penny L. Moore, Mia Coetzer, & Lynn Morris. (2005). In Vitro Generation of HIV Type 1 Subtype C Isolates Resistant to Enfuvirtide. AIDS Research and Human Retroviruses. 21(9). 776–783. 10 indexed citations

20.

Moore, Penny L., Pippa Oakeshott, Jacqueline Logan, John Law, & D. M. Harris. (1990). Prophylaxis against hepatitis A for travel.. BMJ. 300(6726). 723–724. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact